Search clinical trials for: CD19 and CD22

Total 473946 results

AbClon

Recruiting

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non Hodgkin Lymphoma

Korea, Republic of
John Lister
Miltenyi Biotec, Inc.; Lentigen Technology, Inc.; AHN (Allegheny Health Network)...

Recruiting

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | B Acute Lymphoblastic Leukemia | B-Cell Lymphoma | Transformed Lymphoma

United States
Hospital Israelita Albert Einstein
Miltenyi Biotec, Inc.

Not yet recruiting

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies (CARTHIAE-1)

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory | Acute Lymphoblastic Leukemia Refractory

Brazil
The Affiliated People's Hospital of Ningbo University
UTC Therapeutics Inc.

Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Lymphoma | Leukemia | Myeloma | Relapsed/Refractory Hematological Malignancies

China
Kyverna Therapeutics

Not yet recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Systemic Sclerosis | Systemic Sclerosis - Diffuse Cutaneous | Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Synthekine

Recruiting

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Shanghai GeneChem Co., Ltd.

Unknown

A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

Leukemia, B-Cell

China
Juno Therapeutics, a Subsidiary of Celgene

Terminated

Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET)

Acute Lymphoblastic Leukemia

United States
Athenex, Inc.

Recruiting

Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (ANCHOR2)

B-cell Lymphoma | CLL/SLL | ALL, Childhood | DLBCL - Diffuse Large B Cell Lymphoma | B-cell Leukemia | NHL, Relapsed, Adult | ALL, Adult B Cell

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

B-ALL

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

B-cell Leukemia

China
Guangdong Ruishun Biotech Co., Ltd
Ruijin Hospital; Southern Medical University, China; Beijing GoBroad Hospital

Not yet recruiting

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

B-cell Non-Hodgkin's Lymphoma
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Neena Kapoor, M.D.

Not yet recruiting

TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Hematologic Malignancy | Graft Vs Host Disease | Graft-versus-host-disease | Non-hematologic Malignancy
Children's Hospital Medical Center, Cincinnati

Withdrawn

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

United States
University Hospital Tuebingen

Recruiting

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (Anti-CD19-ALL)

ALL, Childhood B-Cell | Acute Lymphoid Leukemia Relapse | Acute Lymphocytic Leukemia Refractory

Germany
Gilead Sciences

Terminated

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Peking University
Marino Biotechnology Co., Ltd.

Unknown

Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma

B-cell Lymphoma

China
Kyverna Therapeutics

Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Lupus Nephritis | Lupus Nephritis - World Health Organization (WHO) Class III | Lupus Nephritis - WHO Class IV

United States
University Hospital Tuebingen

Terminated

Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia (CD3/CD19 Haplo)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

Germany
Changhai Hospital
Rui Therapeutics Co., Ltd

Recruiting

An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)

China
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; 920th Hospital of Joint Logistics Support... and other collaborators

Not yet recruiting

Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

Lymphoma, Non-Hodgkin

China
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

B-cell Lymphoma

China
Beijing Tsinghua Chang Gung Hospital
China Immunotech Pharmaceuticals Co.Ltd.

Suspended

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

B-cell Non-Hodgkin's Lymphoma

China
Stephan Grupp MD PhD
University of Pennsylvania

Recruiting

Orphan Indications for CD19 Redirected Autologous T Cells

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL | Infants With Very High Risk KMT2A B-ALL | Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation

United States
Changchun Deng, MD

Active, not recruiting

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

Non Hodgkin Lymphoma

United States
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Chongqing University... and other collaborators

Unknown

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

B Cell Leukemia | Relapsed Adult ALL

China
Southwest Hospital, China

Unknown

a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies

Lymphoma, Large B-Cell, Diffuse | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma，Malignant

China
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) (BAH242)

Autoimmune Diseases | Systemic Lupus Erythematosus | Systemic Sclerosis | Lupus Nephritis | Microscopic Polyangiitis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Sjogren's Syndrome | Idiopathic Inflammatory Myopathies | Granulomatous Polyangiitis

China
Han weidong

Recruiting

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | Decitabine-primed Tandem CD19/CD20 CAR T Cells

China
Gracell Biopharmaceuticals, Inc.

Recruiting

A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

United States
Wuhan Union Hospital, China
Shanghai Simnova Biotechnology Co.,Ltd.

Recruiting

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia | Non Hodgkin's Lymphoma

China
Juventas Cell Therapy Ltd.

Completed

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma

Diffuse Non-Hodgkin Lymphoma

China
Juventas Cell Therapy Ltd.

Completed

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Relapsed or Refractory Acute Lymphoblastic Leukemia

China
C. Babis Andreadis
University of California, Davis

Recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Transformed Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital...
Juventas Cell Therapy Ltd.

Recruiting

CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Autoimmune Hemolytic Anemia | Autologous CD19 CAR-T | Failure of Three or More Lines of Therapy

China
Chulalongkorn University
King Chulalongkorn Memorial Hospital; Health Systems Research Institute

Recruiting

Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.

SLE (Systemic Lupus)

Thailand
M.D. Anderson Cancer Center
Ziopharm Oncology

Completed

Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

Lymphoma | Leukemia

United States
National University Health System, Singapore

Suspended

Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia

Singapore
National Cancer Institute (NCI)

Active, not recruiting

CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

Lymphoblastic Leukemia, Acute, Childhood | Leukemia, Acute Lymphoblastic

United States
Vinmec Research Institute of Stem Cell and Gene...
National Institute of Hematology and Blood Transfusion, Vietnam

Recruiting

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

B-Cell Non Hodgkin Lymphoma | B-Cell Acute Lymphoblastic Leukemia

Vietnam
Stephan Grupp MD PhD
Children's Hospital of Philadelphia

Recruiting

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

B Cell Acute Lymphoblastic Leukemia (B-ALL) | B Lineage Lymphoblastic Lymphoma

United States
Ottawa Hospital Research Institute

Recruiting

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01)

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

Canada
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Refractory | B-Cell Lymphoma Stage I | Relapsed

China
Fujian Medical University

Unknown

CART-19 Cells For MRD Positive CD19+ ALL (CCFMPCA)

Acute Lymphoblastic Leukemia

China
Kyverna Therapeutics

Recruiting

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis (KYSA-3)

Lupus Nephritis | Lupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class III

Germany
Pell Bio-Med Technology Co., Ltd.

Recruiting

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma | Follicular Lymphoma Grade 3B | Follicular Lymphoma Grade 3A

Taiwan
University of Colorado, Denver

Not yet recruiting

TCR Alpha/Beta and CD19-deplete Haplo-HSCT

Hematologic Malignancy | Pediatric Patients | Other Hematologic Condition

United States
Medical College of Wisconsin
University of Wisconsin, Madison; Amgen

Recruiting

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

B-cell Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | B-Cell ALL, Childhood

United States
The Children's Hospital of Zhejiang University...
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China

Search clinical trials for: CD19 and CD22

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations